| Literature DB >> 33944820 |
Serena Ferretti1, Antonio Gatto2, Antonietta Curatola3, Valeria Pansini4, Benedetta Graglia5, Antonio Chiaretti6.
Abstract
INTRODUCTION: Reye syndrome is a rare acquired metabolic disorder appearing almost always during childhood. Its aetiopathogenesis, although controversial, is partially understood. The classical disease is typically anticipated by a viral infection with 3-5 days of well-being before the onset of symptoms, while the biochemical explanation of the clinical picture is a mitochondrial metabolism disorder, which leads to a metabolic failure of different tissues, especially the liver. Hypothetically, an atypical response to the preceding viral infection may cause the syndrome and host genetic factors and different exogenous agents, such as toxic substances and drugs, may play a critical role in this process. Reye syndrome occurs with vomiting, liver dysfunction and acute encephalopathy, characterized by lack of inflammatory signs, but associated with increase of intracranial pressure and brain swelling. Moreover, renal and cardiac dysfunction can occur. Metabolic acidosis is always detected, but diagnostic criteria are not specific. Therapeutic strategies are predominantly symptomatic, in order to manage the clinical and metabolic dysfunctions. CASE REPORTS: We describe three cases of children affected by Reye syndrome with some atypical features, characterized by no intake of potentially trigger substances, transient hematological changes and dissociation between hepatic metabolic impairment, severe electroencephalographic slowdown and slightly altered neurological examination.Entities:
Year: 2021 PMID: 33944820 PMCID: PMC8142747 DOI: 10.23750/abm.v92iS1.10205
Source DB: PubMed Journal: Acta Biomed ISSN: 0392-4203
Differential diagnosis of Reye Syndrome.
| RS | Viral hepatitis | Drugs or other toxic substances* | Congenital metabolic disorders** | |
| Infectious (viral) prodromes | + | + | - | +/- |
| Previous intake of: | ||||
| Drugs | +/- | - | ++ | - |
| Salicylates | + | - | - | - |
| Encephalopathy | ++ | +/- | - | + |
| Hypertransaminasemia | ++ (Always) | ++ | + | + |
| Hyperbilirubinemia | - | + | + | +/- |
| Haemocoagulative alterations | ++ (Usually) | +/- | - | +/- |
| Serum LDH increase | ++ | +/- | - | + |
| Hyperammonemia | ++ (Usually) | +/- | - | ++ |
| Hypoglycemia | + | +/- | - | - |
| Normal CSF | ++ (Always) | ++ | + | +/- |
* Drugs: 6-mercaptopurine, methotrexate, halothane, acetaminophen, anti-TB drugs.
Other toxic substances: lead, aflatoxins.
**Metabolic disorders: altered urea cycle, altered fatty acid metabolism, altered metabolism of branched-chain amino acids, fructose intolerance.
Comparison between our case reports and classical Reye Syndrome.
| RS | Case 1 (B.C.) | Case 2 (D.S.) | Case 3 (C.F.) | |
| Age (years) | 3-14 | 5 | 4 | 3 |
| Infectious (viral) prodromes | Yes | Yes | Yes | Perhaps (+/-) |
| Previous intake of salicylates | Yes | No | No | Yes |
| Vomiting | Yes | Yes | Yes | No |
| Clinical neurological changes | Yes | Yes (+) | Yes | Yes (+) |
| EEG alterations | Yes | Yes (+++) | Yes | Yes (+++) |
| Jaundice | No | No | No | No |
| Hypertransaminasemia, LDH increase | Yes | Yes (++) | Yes | Yes |
| Hyperammonemia | Yes | Yes | Yes | Yes (+/-) |
| Haemocoagulative alterations | Yes | Yes | Yes (++) | Yes (++) |
| Leukopenia and/or thrombocytopenia | No | Yes | Yes | No |
| Hyperamylasaemia | Yes (in case of pancreatitis) | No | No | No |
| Hypoglycemia | Yes | No | No | No |
| Normal CSF | Yes | Yes | Yes | Yes |